Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 15
Partnerships 16
Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16
Chi-Med Forms Joint Venture with Sinopharm 17
Mitsubishi Forms Joint Venture With Sinopharm 18
China NT Pharma To Form Joint Venture With Sinopharm 19
China State Institute of Pharma Enters Into Research Agreement With Sanofi 20
Aeras Enters Into Co-Development Agreement With China National Biotech Group 21
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 22
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 23
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 24
Licensing Agreements 25
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 25
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 26
Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 28
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 30
Equity Offering 31
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 31
Sinopharm to Raise USD728 Million in Private Placement of Shares 32
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 34
Sinopharm Completes Private Placement Of Shares For US$525 Million 35
China National Biotech Plans To Complete IPO For US$1.5 Billion 37
Debt Offering 38
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 38
China National Biotec Plans Public Offering Of Notes Due 2015 For US$126 Million 39
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million 40
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million 41
Acquisition 42
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 42
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 43
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 44
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 45
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 46
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 48
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 49
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 50
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 51
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million 52
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million 54
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 55
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 56
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 57
Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For US$33 Million 58
China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For US$1.4 Million 59
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 60
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 61
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 62
China National Pharmaceutical Group Corp – Key Competitors 63
China National Pharmaceutical Group Corp – Key Employees 64
China National Pharmaceutical Group Corp – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 2
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
China National Pharmaceutical Group Corp, Deals By Therapy Area, 2011 to YTD 2017 10
China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 15
Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16
Chi-Med Forms Joint Venture with Sinopharm 17
Mitsubishi Forms Joint Venture With Sinopharm 18
China NT Pharma To Form Joint Venture With Sinopharm 19
China State Institute of Pharma Enters Into Research Agreement With Sanofi 20
Aeras Enters Into Co-Development Agreement With China National Biotech Group 21
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 22
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 23
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 24
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 25
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 26
Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 28
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 30
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 31
Sinopharm to Raise USD728 Million in Private Placement of Shares 32
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 34
Sinopharm Completes Private Placement Of Shares For US$525 Million 35
China National Biotech Plans To Complete IPO For US$1.5 Billion 37
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 38
China National Biotec Plans Public Offering Of Notes Due 2015 For US$126 Million 39
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million 40
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million 41
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 42
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 43
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 44
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 45
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 46
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 48
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 49
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 50
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 51
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million 52
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million 54
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 55
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 56
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 57
Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For US$33 Million 58
China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For US$1.4 Million 59
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 60
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 61
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 62
China National Pharmaceutical Group Corp, Key Competitors 63
China National Pharmaceutical Group Corp, Key Employees 64
China National Pharmaceutical Group Corp, Subsidiaries 65
